HomeCompareGLAPF vs MRK

GLAPF vs MRK: Dividend Comparison 2026

GLAPF yields 2.14% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GLAPF wins by $77.7K in total portfolio value· pulled ahead in Year 5
10 years
GLAPF
GLAPF
● Live price
2.14%
Share price
$19.80
Annual div
$0.42
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$134.5K
Annual income
$54,894.60
Full GLAPF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — GLAPF vs MRK

📍 GLAPF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGLAPFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GLAPF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GLAPF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GLAPF
Annual income on $10K today (after 15% tax)
$182.24/yr
After 10yr DRIP, annual income (after tax)
$46,660.41/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, GLAPF beats the other by $38,332.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GLAPF + MRK for your $10,000?

GLAPF: 50%MRK: 50%
100% MRK50/50100% GLAPF
Portfolio after 10yr
$95.6K
Annual income
$32,346.37/yr
Blended yield
33.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GLAPF
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
4.3
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GLAPF buys
0
MRK buys
0
No recent congressional trades found for GLAPF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGLAPFMRK
Forward yield2.14%2.76%
Annual dividend / share$0.42$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR51.4%32.7%
Portfolio after 10y$134.5K$56.8K
Annual income after 10y$54,894.60$9,798.13
Total dividends collected$106.2K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: GLAPF vs MRK ($10,000, DRIP)

YearGLAPF PortfolioGLAPF Income/yrMRK PortfolioMRK Income/yrGap
1$11,025$324.60$11,206$366.19$181.00MRK
2$12,303$506.35$12,650$502.35$347.00MRK
3$13,963$799.53$14,407$694.19$444.00MRK
4$16,225$1,284.00$16,585$967.82$360.00MRK
5← crossover$19,472$2,111.04$19,342$1,363.89+$130.00GLAPF
6$24,419$3,584.77$22,913$1,947.19+$1.5KGLAPF
7$32,490$6,361.15$27,662$2,823.89+$4.8KGLAPF
8$46,740$11,975.45$34,159$4,173.35+$12.6KGLAPF
9$74,388$24,376.47$43,337$6,308.80+$31.1KGLAPF
10$134,490$54,894.60$56,776$9,798.13+$77.7KGLAPF

GLAPF vs MRK: Complete Analysis 2026

GLAPFStock

Glanbia plc operates as a nutrition company worldwide. The company manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, online, and gyms, as well the food, drug, mass, and club channels. It engages in the manufacture and sale of cheese, dairy, and non-dairy nutritional and functional ingredients, and vitamin and mineral premixes. In addition, the company engages in the financing, research and development, property and land dealing, receivables management, management, property leasing, business service, and weight management solutions businesses. It operates a portfolio of brands, including OPTIMUM NUTRITION, SlimFast, BSN, ISOPURE, NUTRAMINO, think!, Amazing Grass, and BODY&FIT brands. Glanbia plc was founded in 1964 and is headquartered in Kilkenny, Ireland.

Full GLAPF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this GLAPF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GLAPF vs SCHDGLAPF vs JEPIGLAPF vs OGLAPF vs KOGLAPF vs MAINGLAPF vs JNJGLAPF vs ABBVGLAPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.